Press Releases

October 10, 2019 at 7:00 AM EDT
Altimmune to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md. , Oct. 10, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will participate in the following investor conferences during the months of October and November:           H.C.
September 9, 2019 at 7:00 AM EDT
Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer
GAITHERSBURG, Md. , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed M. Scott Harris , M.D. as Chief Medical Officer. Dr. Harris is succeeding Dr. Sybil Tasker , who resigned June 30, 2019 to continue her
August 5, 2019 at 7:00 AM EDT
Altimmune to Announce Second Quarter 2019 Financial Results on August 14
GAITHERSBURG, Md. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it will report financial results for the three and six months ended June 30, 2019
July 15, 2019 at 7:00 AM EDT
Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc.
GAITHERSBURG, Md. , July 15, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of Spitfire Pharma, Inc. , including the product candidate ALT-801, a potent GLP-1/Glucagon receptor
Displaying 1 - 10 of 23

Investor Contact

Ashley Robinson
LifeSci Advisors, LLC

Email: arr@lifesciadvisors.com

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe